Shares of bio-pharmaceutical company Innoviva (NASDAQ: INVA) fell as much as 17.4% on Wednesday. But the stock finished the trading day down 15.55%.
Continue Reading Below
The stock's decline came just before Innoviva was scheduled to report its results for its third quarter. While there wasn't any specific news that seemed to drive the stock's decline, the timing of the sell-off indicates a large investor may have decided to sell a meaningful position just before earnings. Similarly, a large number of smaller investors may have happened to sell on the same day.
It's impossible to know exactly why the stock traded lower in these cases. But it looks as if shares recovered somewhat in after-hours trading, when Innoviva reported its third-quarter earnings. At the time of this writing, the stock is up 3% in after-hours trading. But there's no guarantee this rebound will hold.
Investors shouldn't read too closely into moves like these. Volatility -- especially for small-cap stocks like Innoviva -- happens from time to time for no specific reason.
Whether there's a reason for the stock's move or not, Innoviva reported total third-quarter revenue of $48.4 million and EPS of $0.21, up from $33 million and $0.13 in the year-ago quarter, respectively. Innoviva CEO Michael Aguiar called it a "very successful third quarter."
10 stocks we like better than Innoviva Common StockWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Innoviva Common Stock wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of October 9, 2017